NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Voyager Therapeutics, Inc. VYGR
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$40.4M
▼ 49.5% vs FY2024
EPS · FY25
$-2.04
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-48.3%
Net margin · FY25
-296.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 40.4M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 297 cents on every revenue dollar this year.
Per share
USD -2.04
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-48.3%
Return on equity, FY2025
ROE
Operating margin-326.6%
Net margin-296.5%
Return on assets-37.1%
Each USD of equity lost 48 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−25.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−0.4%
−25.1%
+8.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+58.0%
Change, 10 years+136.8%
The share count grew 58% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 252.3M
total assets, end of FY2025
Total assetsUSD 252.3M
EquityUSD 196.1M
CashUSD 65.3M
Current ratio7.64×
Equity funds 78% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.1
0.3
0.0
0.0
0.2
0.1
0.0
0.0
0.0
0.0
·
Operating income $B
−0.1
−0.1
0.1
−0.1
−0.1
0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
0.1
−0.0
−0.1
0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
·
·
·
−0.0
·
0.0
0.0
·
Net income $B
−0.1
−0.1
0.1
−0.0
−0.1
0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−2.04
−1.13
2.97
−1.21
−1.89
0.98
−1.21
−2.75
−2.64
−1.59
9.14
27.83
Dividend / sh $
·
·
·
·
0.00
0.00
0.00
0.00
·
·
0.00
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−48.3
−24.3
89.6
−60.2
−57.1
28.9
−59.7
−97.8
−52.4
−26.4
−40.0
·
Shares out B
0.06
0.05
0.04
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.02
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed